Drugs containing Famotidine: Pepcid, Pepcid AC, Pepcid Complete, Heartburn Relief, Duexis, Fluxid, Pepcid AC Maximum Strength, Zantac 360, Pepcid Oral Suspension, Pepcid AC Chewable Tablets, Show all 28 »Duo Fusion, Pepcid RPD, Pepcid AC Maximum Strength Tablets, Acid Reducer-Famotidine, Acid Controller Complete Dual Action, Dual Action Complete, Complete Acid Reducer plus Antacid, Dual-Action Acid Controller Complete, Tums Dual Action, Acid Reducer Plus Antacid, Acid Controller Complete, Acid Reducer Original Strength, Acid Reducer Maximum Strength, Heartburn Relief Maximum Strength, Acid Controller Original Strength, Mylanta AR, Acid Controller Maximum Strength, Acid Control
Famotidine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Famotidine doses in breastmilk result in infant dosages that are lower than those used in newborn infants. Famotidine would not be expected to cause any adverse effects in breastfed infants. No special precautions are required.
Drug Levels
Maternal Levels. Eight women who had "recently given birth" (not defined, but apparently within a few days postpartum) were given famotidine 40 mg orally. An average peak breastmilk level of 72 mcg/L occurred 6 hours after the dose.[1] Using the peak milk level data from this study, an exclusively breastfed infant would receive an estimated maximum of 0.01 mg/kg daily with this maternal dosage regimen or less than 2% of the maternal weight-adjusted dosage.
Seven women were given oral famotidine 40 mg daily in 2 or 4 divided doses for 3 days at 12 to 16 weeks postpartum. Average concentrations of famotidine in breastmilk were 53 and 55 mcg/L at 3 and 6 hours after a dose, respectively.[2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Histamine H2-receptor blockade is known to stimulate prolactin secretion.[3] Oral famotidine usually does not affect serum prolactin levels, but rare cases of hyperprolactinemia and galactorrhea have been reported.[4,5] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Courtney TP, Shaw RW, Cedar E, et al. Excretion of famotidine in breast milk. Br J Clin Pharmacol 1988;26:615p-78p.
2.
Wang X, Zhan Y, Hankins GD, et al. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol 2011;204 (1 Suppl) :S72-3.
3.
Knigge UP. Histaminergic regulation of prolactin secretion. Dan Med Bull 1990;37:109-24. [PubMed: 2188799]
4.
Delpre G, Lapidot M, Lipchitz A, et al. Hyperprolactinaemia during famotidine therapy. Lancet 1993;342:868. [PubMed: 8104296]
5.
Güven K, Kelestimur F. Hyperprolactinemia and galactorrhea with standard-dose famotidine therapy. Ann Pharmacother 1995;29:788. [PubMed: 8520102]
Substance Identification
Substance Name
Famotidine
CAS Registry Number
76824-35-6
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Ulcer Agents
Histamine H2 Antagonists
Gastrointestinal Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
